Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf(Pearson (United States)), Allard Kaptein
Cited by 366
Related Papers
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890